<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Asthma medications for acute symptom relief in children &lt;12 years of age*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Asthma medications for acute symptom relief in children &lt;12 years of age*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Asthma medications for acute symptom relief in children &lt;12 years of age*</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="15%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose form</td> <td class="subtitle1">0 to &lt;4 years</td> <td class="subtitle1">4 to 11 years</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_bottom divider_top"> <td class="subtitle2_left" colspan="5">Inhaled short-acting beta<sub>2</sub>-agonists (SABAs)</td> </tr> <tr> <td class="subtitle3_left" colspan="5">Metered dose inhaler (MDI)</td> </tr> <tr> <td class="indent2">Albuterol (salbutamol) HFA MDI with spacer (valved holding chamber)</td> <td> <ul> <li>90 mcg/puff</li> </ul> </td> <td> <ul> <li>2 puffs up to every 4 hours as needed</li> </ul> </td> <td> <ul> <li>2 puffs up to every 4 hours as needed</li> </ul> </td> <td class="divider_bottom" rowspan="2"> <ul> <li>Differences in potencies exist, but products shown are essentially comparable on a per-puff basis.</li> <li>An increasing use or lack of expected effect indicates diminished control of asthma.</li> <li>Not recommended for long-term daily treatment. Regular use exceeding 2 days/week for symptom control (not prevention of EIB) indicates the need for additional long-term control therapy.</li> <li>Periodically clean mouthpiece as drug may plug orifice.</li> <li>Inhaler should be administered using a valved holding chamber; add a mask for children &lt;4 years of age.</li> <li>Instructions for use, priming, and cleaning MDI vary by brand. For specific information, refer to UpToDate topic on use of inhaler devices in children, Lexicomp, and patient leaflet included with MDI.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Levalbuterol (levosalbutamol) HFA MDI with spacer (valved holding chamber)</td> <td> <ul> <li>45 mcg/puff</li> </ul> </td> <td> <ul> <li>Safety and efficacy not established in children &lt;4 years</li> </ul> </td> <td> <ul> <li>2 puffs up to every 4 hours as needed</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="5">Dry powder inhaler (DPI)</td> </tr> <tr class="divider_bottom"> <td class="indent2">Albuterol (salbutamol) breath-activated DPI</td> <td> <ul> <li>90 mcg/inhalation</li> </ul> </td> <td> <ul> <li>Safety and efficacy not established in children &lt;4 years</li> </ul> </td> <td> <ul> <li>2 puffs up to every 4 hours as needed</li> </ul> </td> <td> <ul> <li>DPI alternative for prophylactic use prior to exercise in older children who are comfortable with and capable of properly using a breath-activated inhaler technique.</li> <li>Use of DPI is not advised as rescue therapy in an acute setting, as some children may be unable to generate sufficient inspiratory flow rate to assure optimal lung deposition of drug.</li> <li><strong>NOTE:</strong> DPIs can contain lactose and trace milk proteins (ie, potential allergens).</li> <li>Also refer to information above on albuterol MDI.</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="5">Nebulizer solution</td> </tr> <tr> <td class="indent2">Albuterol (salbutamol)</td> <td> <ul> <li>0.63 mg/3 mL</li> <li>1.25 mg/3 mL</li> <li>2.5 mg/3 mL</li> <li>5 mg/mL (0.5%)</li> </ul> </td> <td> <ul> <li>0.63 to 2.5 mg up to every 4 hours, as needed</li> </ul> </td> <td> <ul> <li>1.25 to 5 mg up to every 4 hours, as needed</li> </ul> </td> <td> <ul> <li>May mix with budesonide suspension, ipratropium solution, or cromolyn sodium solution for nebulization.</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Levalbuterol (levosalbutamol)</td> <td> <ul> <li>0.31 mg/3 mL</li> <li>0.63 mg/3 mL</li> <li>1.25 mg/0.5 mL</li> <li>1.25 mg/3 mL</li> </ul> </td> <td> <ul> <li>0.31 to 1.25 mg up to every 4 hours, as needed</li> </ul> </td> <td> <ul> <li>0.31 to 0.63 mg up to every 4 hours, as needed</li> </ul> </td> <td> <ul> <li>May mix with budesonide suspension for nebulization.</li> </ul> </td> </tr> <tr> <td class="subtitle3_left" colspan="5">Combination inhaled rapid-onset long-acting beta agonist and glucocorticoid</td> </tr> <tr> <td class="indent2">Budesonide-formoterol MDI</td> <td> <ul> <li>Budesonide 80 mcg-formoterol 4.5 mcg/puff</li> </ul> </td> <td> <ul> <li>Safety and efficacy not established in children &lt;6 years</li> </ul> </td> <td> <ul> <li>1 to 2 inhalations every 4 hours, as needed, in addition to 2 inhalations daily as maintenance therapy (maximum total daily dose 8 puffs)</li> </ul> </td> <td> <ul> <li>Single maintenance and reliever therapy (SMART) is off-label in the US. Studies of SMART used DPI, but only the MDI is available in the US. There is a small amount of variability in the amount of drug dispensed with each MDI actuation, whereas the DPI dosing is consistent. Thus, 2 puff dosing is preferred for the MDI.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Use and dose adjustment of inhaled short-acting beta<sub>2</sub>-agonists for acute asthma exacerbations are reviewed separately. Short-acting beta agonists (SABAs) can also be used to prevent exercise-induced bronchoconstriction, 2 inhalations administered 10 to 20 minutes prior to exercise. In addition, higher doses of SABAs may be used to treat acute exacerbations, and they may be given more frequently than every 4 hours when patients are in a medically supervised, urgent-care setting. Refer to separate UpToDate topic reviews and tables on recommended doses of medications to treat children with an acute asthma exacerbation.</li>
<li>Nonselective inhaled agents (ie, epinephrine, isoproterenol, metaproterenol) and orally administered beta<sub>2</sub>-agonists are not recommended, due to their potential for excessive cardiac stimulation, especially in high doses.</li>
</ul></div><div class="graphic_footnotes">DPI: dry powder inhaler; EIB: exercise-induced bronchospasm; HFA: hydrofluoroalkane; MDI: metered-dose inhaler.<br/>* Doses are provided for those products that have been approved by the US Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use. Doses shown and strengths (ie, mcg per puff or inhalation) are based upon product descriptions approved in the United States, which may differ from how strengths are described for products available in other countries. Consult local product information before use.</div><div class="graphic_reference">Data from:
<ol>
<li>National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</li>
<li>2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. <a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines" target="_blank">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a> (Accessed on October 18, 2021).</li>
<li>Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, updated 2021. <a href="https://ginasthma.org/reports/" target="_blank">https://ginasthma.org/reports/</a> (Accessed on October 18, 2021).</li>
<li>Lexicomp Online. Copyright Â© 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
</ol></div><div id="graphicVersion">Graphic 59229 Version 23.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
